D. Ricard, A. Idbaih, and F. Ducray, Primary brain tumours in adults, Lancet, vol.379, issue.11, pp.61346-61355, 2012.

D. N. Louis, A. Perry, G. Reifenberger, A. Von-deimling, D. Figarella-branger et al., The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathologica, vol.131, issue.6, pp.803-820, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01479018

R. Stupp, W. P. Mason, M. J. Van-den-bent, M. Weller, B. Fisher et al., Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, New England Journal of Medicine, vol.352, issue.10, pp.987-996, 2005.

R. Stupp, M. E. Hegi, and W. P. Mason, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol, vol.10, pp.70025-70032, 2009.

N. M. Bleehen and S. P. Stenning, A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma, British Journal of Cancer, vol.64, issue.4, pp.769-774, 1991.

C. G. Patil, M. Nuño, A. Elramsisy, D. Mukherjee, C. Carico et al., High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era, Neuro-Oncology, vol.15, issue.1, pp.104-111, 2012.

T. Hideshima, M. Akiyama, T. Hayashi, P. Richardson, R. Schlossman et al., Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu, Blood, vol.101, issue.2, pp.703-705, 2003.

T. Hideshima, K. Podar, D. Chauhan, K. Ishitsuka, C. Mitsiades et al., p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells, Oncogene, vol.23, issue.54, pp.8766-8776, 2004.

R. M. Campbell, B. D. Anderson, N. A. Brooks, H. B. Brooks, E. M. Chan et al., Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity, Molecular Cancer Therapeutics, vol.13, issue.2, pp.364-374, 2013.

J. Starling, R. Campbell, and C. Shih, Correction: A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer, Clinical Cancer Research, vol.22, issue.10, pp.2596-2596, 2016.

A. Patnaik, P. Haluska, A. W. Tolcher, C. Erlichman, K. P. Papadopoulos et al., A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer, Clinical Cancer Research, vol.22, issue.5, pp.1095-1102, 2015.

I. Vergote, F. Heitz, P. Buderath, M. Powell, J. Sehouli et al., A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer, Gynecologic Oncology, vol.156, issue.1, pp.23-31, 2020.

J. C. Bendell, H. G. Bischoff, J. Hwang, H. C. Reinhardt, T. Zander et al., A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer, Investigational New Drugs, vol.38, issue.4, pp.1145-1155, 2019.

J. Li, M. Wang, M. Won, E. G. Shaw, C. Coughlin et al., Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma, International Journal of Radiation Oncology*Biology*Physics, vol.81, issue.3, pp.623-630, 2011.

Y. K. Cheung and R. Chappell, Sequential Designs for Phase I Clinical Trials with Late-Onset Toxicities, Biometrics, vol.56, issue.4, pp.1177-1182, 2000.

P. Y. Wen, D. R. Macdonald, D. A. Reardon, T. F. Cloughesy, A. G. Sorensen et al., Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group, Journal of Clinical Oncology, vol.28, issue.11, pp.1963-1972, 2010.

C. Villalva, U. Cortes, M. Wager, J. Tourani, P. Rivet et al., O6-Methylguanine-Methyltransferase (MGMT) Promoter Methylation Status in Glioma Stem-Like Cells is Correlated to Temozolomide Sensitivity Under Differentiation-Promoting Conditions, International Journal of Molecular Sciences, vol.13, issue.6, pp.6983-6994, 2012.

K. L. Mcdonald, R. W. Rapkins, J. Olivier, L. Zhao, K. Nozue et al., The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients, European Journal of Cancer, vol.49, issue.2, pp.360-368, 2013.

J. L. Clarke, F. M. Iwamoto, J. Sul, K. Panageas, A. B. Lassman et al., Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma, Journal of Clinical Oncology, vol.27, issue.23, pp.3861-3867, 2009.

S. Yang, M. Kim, T. Lee, K. Lee, S. Jeun et al., Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas, Journal of Korean Medical Science, vol.21, issue.4, p.739, 2006.

J. G. Pérez-larraya, F. Ducray, O. Chinot, I. Catry-thomas, L. Taillandier et al., Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial, Journal of Clinical Oncology, vol.29, issue.22, pp.3050-3055, 2011.

S. Dixit, L. Baker, V. Walmsley, and M. Hingorani, Temozolomide-related idiosyncratic and other uncommon toxicities, Anti-Cancer Drugs, vol.23, issue.10, pp.1099-1106, 2012.

M. Niewald, C. Berdel, J. Fleckenstein, N. Licht, R. Ketter et al., Toxicity after radiochemotherapy for glioblastoma using temozolomide - a retrospective evaluation, Radiation Oncology, vol.6, issue.1, p.141, 2011.

W. Wick, M. Platten, C. Meisner, J. Felsberg, G. Tabatabai et al., Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial, The Lancet Oncology, vol.13, issue.7, pp.707-715, 2012.

J. Grewal, C. A. Dellinger, and W. K. Yung, Fatal Reactivation of Hepatitis B with Temozolomide, New England Journal of Medicine, vol.356, issue.15, pp.1591-1592, 2007.

A. Goldbecker, A. B. Tryc, P. Raab, H. Worthmann, J. Herrmann et al., Hepatic encephalopathy after treatment with temozolomide, Journal of Neuro-Oncology, vol.103, issue.1, pp.163-166, 2010.

G. Sarganas, H. D. Orzechowski, A. Klimpel, M. Thomae, W. Kauffmann et al., Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system, Neuro-Oncology, vol.14, issue.5, pp.541-546, 2012.

S. Dixit, D. Salvage, C. Rajaraman, M. Hingorani, and C. Rowland-hill, Hypernatremia-associated myelinolysis following the management of sepsis in a patient with glioblastoma treated with radiotherapy and temozolomide, Acta Neurologica Belgica, vol.113, issue.4, pp.527-530, 2013.

T. Hideshima, K. Podar, D. Chauhan, K. Ishitsuka, C. Mitsiades et al., p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells, Oncogene, vol.23, issue.54, pp.8766-8776, 2004.

T. A. Navas, A. N. Nguyen, T. Hideshima, M. Reddy, J. Y. Ma et al., Inhibition of p38? MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-XL, Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo, Leukemia, vol.20, issue.6, pp.1017-1027, 2006.

K. Vanderkerken, S. Medicherla, L. Coulton, H. De-raeve, A. Willems et al., Inhibition of p38 Mitogen-Activated Protein Kinase Prevents the Development of Osteolytic Bone Disease, Reduces Tumor Burden, and Increases Survival in Murine Models of Multiple Myeloma, Cancer Research, vol.67, issue.10, pp.4572-4577, 2007.

H. Yasui, T. Hideshima, H. Ikeda, J. Jin, E. M. Ocio et al., BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth, British Journal of Haematology, vol.136, issue.3, pp.414-423, 2007.

D. He, X. Zhao, X. Chen, Y. Fang, S. Singh et al., BIRB796, the Inhibitor of p38 Mitogen-Activated Protein Kinase, Enhances the Efficacy of Chemotherapeutic Agents in ABCB1 Overexpression Cells, PLoS ONE, vol.8, issue.1, p.e54181, 2013.

X. Jin, Q. Mo, Y. Zhang, Y. Gao, Y. Wu et al., The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer, Cancer Biology & Therapy, vol.17, issue.5, pp.566-576, 2016.

Y. T. Yeung, S. Yin, B. Lu, S. Fan, R. Yang et al., Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization, EBioMedicine, vol.28, pp.51-61, 2018.

S. Schreiber, B. Feagan, G. D?haens, J. Colombel, K. Geboes et al., Oral p38 Mitogen-Activated Protein Kinase Inhibition With BIRB 796 for Active Crohn?s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial, Clinical Gastroenterology and Hepatology, vol.4, issue.3, pp.325-334, 2006.

L. Sokol, L. Cripe, H. Kantarjian, M. A. Sekeres, S. Parmar et al., Randomized, dose-escalation study of the p38? MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome, Leukemia, vol.27, issue.4, pp.977-980, 2012.

L. K. Newby, M. S. Marber, and C. Melloni, Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: A randomised phase 2 trial, The Lancet, vol.384, pp.60417-60424, 2014.